Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Shi, Qin ^a   Abusarah, Jamilah ^a   Baroudi, Ghayath ^a   Fernandes, Julio C ^a   Fahmi, Hassan ^a   Benderdour, Mohamed ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GLUTATHIONE; ISOCITRATE DEHYDROGENASE; MESSENGER RNA; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; 4-HYDROXY-2-NONENAL; ALDEHYDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; LIPID PEROXIDATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOOD; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART MITOCHONDRION; HEART MUSCLE; LEWIS RAT; METABOLISM; PATHOLOGY;

ALDEHYDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; LIPID PEROXIDATION; MITOCHONDRIA, HEART; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RAMIPRIL; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867528089     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4062     Document Type: Article

References (65)

1. Williams RO, Feldmann M, Maini RN. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis 2000, 59:i75-i80. 10.1136/ard.59.suppl_1.i75, 1766633, 11053094.
2. Choi EM. Oxidative status of DBA/1J mice with type II collagen-induced arthritis. J Appl Toxicol 2007, 27:472-481. 10.1002/jat.1228, 17299831.
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307. 10.1161/01.CIR.0000054612.26458.B2, 12628952.
4. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732. 10.1002/art.20878, 15751097.
5. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83:456S-460S.
6. Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, Crow MK, Sammaritano L, Levine DM, Salmon JE. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009, 60:22-29. 10.1002/art.24148, 2626148, 19116901.
7. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004, 43:2207-2215. 10.1016/j.jacc.2003.11.064, 15193681.
8. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P, Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117:2262-2269. 10.1161/CIRCULATIONAHA.107.734384, 18427133.
9. de Jong HJ, Vandebriel RJ, Saldi SR, van DL, van LH, Cohen Tervaert JW, Klungel OH. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol Drug Saf 2012, 21:835-43. 10.1002/pds.3291, 22674737.
10. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 2000, 899:136-147.
11. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003, 14:421-430. 10.1097/00041433-200310000-00002, 14501580.
12. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 2000, 28:1685-1696. 10.1016/S0891-5849(00)00226-4, 10946210.
13. Kalpakcioglu B, Senel K. The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol 2008, 27:141-145. 10.1007/s10067-007-0746-3, 17912575.
14. Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther 2004, 6:265-278. 10.1186/ar1447, 1064874, 15535839.
15. Lemarechal H, Allanore Y, Chenevier-Gobeaux C, Ekindjian OG, Kahan A, Borderie D. High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. Clin Chim Acta 2006, 367:156-161. 10.1016/j.cca.2005.12.006, 16458876.
16. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009, 73:977-985. 10.1253/circj.CJ-09-0274, 19430165.
17. Rho YH, Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Raggi P, Milne GL, Stein CM. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res 2010, 62:1473-1480.
18. Khan F, Siddiqui AA. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. Clin Chim Acta 2006, 370:100-107. 10.1016/j.cca.2006.01.020, 16513103.
19. Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem 2008, 49:325-350. 10.1007/978-1-4020-8830-8_12, 18751917.
20. Zarkovic N. 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Aspects Med 2003, 24:281-291. 10.1016/S0098-2997(03)00023-2, 12893006.
21. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991, 11:81-128. 10.1016/0891-5849(91)90192-6, 1937131.
22. Awasthi YC, Sharma R, Cheng JZ, Yang Y, Sharma A, Singhal SS, Awasthi S. Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. Mol Aspects Med 2003, 24:219-230. 10.1016/S0098-2997(03)00017-7, 12893000.
23. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 2000, 50:315-321. 10.1080/15216540051081092, 11327326.
24. Fernandes JC, Wang H, Jreyssaty C, Benderdour M, Lavigne P, Qiu X, Winnik FM, Zhang X, Dai K, Shi Q. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther 2008, 16:1243-1251. 10.1038/mt.2008.99, 18500247.
25. Vaillancourt F, Silva P, Shi Q, Fahmi H, Fernandes JC, Benderdour M. Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. J Cell Biochem 2011, 112:107-117. 10.1002/jcb.22884, 20872780.
26. Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M. Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum 2006, 54:271-281. 10.1002/art.21559, 16385544.
27. Benderdour M, Charron G, Deblois D, Comte B, Des Rosiers C. Cardiac mitochondrial NADP+-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation: an event that precedes hypertrophy development. J Biol Chem 2003, 278:45154-45159. 10.1074/jbc.M306285200, 12960146.
28. Chen SH, Fahmi H, Shi Q, Benderdour M. Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes. Arthritis Res Ther 2010, 12:R21. 10.1186/ar2926, 2875653, 20144213.
29. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 1994, 89:397-410. 10.1007/BF00788278, 7535519.
30. Hawat G, Benderdour M, Rousseau G, Baroudi G. Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflugers Arch 2010, 460:583-592. 10.1007/s00424-010-0849-6, 20514543.
31. Murakami K, Haneda M, Makino T, Yoshino M. Protective effect of NADP-isocitrate dehydrogenase on the paraquat-mediated oxidative inactivation of aconitase in heart mitochondria. Environ Toxicol Pharmacol 2006, 22:148-152. 10.1016/j.etap.2006.02.001, 21783702.
32. Le Corvoisier P, Adamy C, Sambin L, Crozatier B, Berdeaux A, Michel JB, Hittinger L, Su J. The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice. Eur J Heart Fail 2010, 12:1171-1178. 10.1093/eurjhf/hfq146, 3290525, 20870672.
33. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards CK. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000, 43:2648-2659. 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M, 11145022.
34. Bingham CO. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl 2002, 65:3-9.
35. Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N, Fox DA, Kashihara N. Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum 2006, 54:1847-1855. 10.1002/art.21891, 16729278.
36. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321:1493-1495. 10.1126/science.1158554, 2741612, 18787169.
37. Lucas DT, Szweda LI. Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc Natl Acad Sci USA 1999, 96:6689-6693. 10.1073/pnas.96.12.6689, 21976, 10359773.
38. Lashin OM, Szweda PA, Szweda LI, Romani AM. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med 2006, 40:886-896. 10.1016/j.freeradbiomed.2005.10.040, 16520240.
39. Poli G, Schaur RJ, Siems WG, Leonarduzzi G. 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med Res Rev 2008, 28:569-631. 10.1002/med.20117, 18058921.
40. Irwin WA, Gaspers LD, Thomas JA. Inhibition of the mitochondrial permeability transition by aldehydes. Biochem Biophys Res Commun 2002, 291:215-219. 10.1006/bbrc.2002.6457, 11846392.
41. Scolletta S, Biagioli B. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed Pharmacother 2010, 64:203-207. 10.1016/j.biopha.2009.10.002, 19954925.
42. Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 2003, 50:319-336.
43. Lee JH, Yang ES, Park JW. Inactivation of NADP+-dependent isocitrate dehydrogenase by peroxynitrite. Implications for cytotoxicity and alcohol-induced liver injury. J Biol Chem 2003, 278:51360-51371. 10.1074/jbc.M302332200, 14551203.
44. Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 2011, 63:1497-1506. 3106129, 21384332.
45. Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 2005, 7:195-207. 10.1186/ar1814, 1257451, 16207349.
46. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278. 10.1016/j.pharmthera.2009.05.002, 19460403.
47. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51. 10.1016/j.cardiores.2004.08.020, 15621032.
48. Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, Sivasubramanian N, Barger PM, Mann DL. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 2011, 124:2106-2116. 10.1161/CIRCULATIONAHA.111.052399, 22025605.
49. Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010, 55:953-960. 10.1161/HYPERTENSIONAHA.109.140608, 20157054.
50. Chiarpotto E, Castello L, Leonarduzzi G, Biasi AF, Poli G. Role of 4-hydroxy-2,3-nonenal in the pathogenesis of fibrosis. Biofactors 2005, 24:229-236. 10.1002/biof.5520240127, 16403983.
51. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, Parola M. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004, 40:60-68.
52. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum 2010, 62:1319-1328.
53. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004, 94:534-541. 10.1161/01.RES.0000115557.25127.8D, 14699015.
54. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 2002, 40:244-250. 10.1161/01.HYP.0000029095.23198.AD, 12215461.
55. Bunkenburg B, van Amelsvoort T, Rogg H, Wood JM. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992, 20:746-754. 10.1161/01.HYP.20.6.746, 1452290.
56. Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997, 95:1910-1917. 10.1161/01.CIR.95.7.1910, 9107180.
57. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003, 92:322-329. 10.1161/01.RES.0000056759.53828.2C, 12595345.
58. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220. 10.1161/01.CIR.0000127949.05756.9D, 15123520.
59. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29:367-374. 10.1016/j.tips.2008.05.003, 18579222.
60. Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 2011, 301:H984-H993. 10.1152/ajpheart.00428.2011, 3191107, 21666115.
61. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 2006, 291:H336-H343. 10.1152/ajpheart.01307.2005, 16489102.
62. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
63. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002, 40:834-839. 10.1161/01.HYP.0000039506.43589.D5, 12468566.
64. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005, 32:2095-2101.
65. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005, 44:24-31.